Article

Medicare cracks down on false claims

Pfizer allegedly promoted four drugs for off-label indications and caused false claims to be submitted to government health care programs for uses that were not medically accepted indications and therefore not covered by those programs.

A $2.3 billion settlement in September between drugmaker Pfizer and the Department of Justice over illegal marketing practices underscores a recent campaign by government agencies to investigate false claims made to Medicare and Medicaid, according to health care attorneys.

Pfizer allegedly promoted four drugs – Bextra, Geodon, Zyvox and Lyrica – for off-label indications and caused false claims to be submitted to government health care programs for uses that were not medically accepted indications and therefore not covered by those programs, according to the Department of Justice.

Giant pharmaceutical companies aren't the only targets of false claims investigations.

Armstrong advises practices to have a compliance program in place to catch potentially fraudulent claims.

Newsletter

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Related Videos
The new standard for medical malpractice: A conversation with Daniel G. Aaron, M.D., J.D.
The new standard for medical malpractice: What to watch for
The new standard for medical malpractice: A step toward ending defensive medicine?
The new standard for medical malpractice: Can doctors be liable for doing what everyone else does?
The new standard for medical malpractice: What makes a clinical guideline legally defensible?
The new standard for medical malpractice: What it means for day-to-day practice
The new standard for medical malpractice: What changed?
The new standard for medical malpractice: Why the law just changed
ACP policy update 2025: A conversation with Brian E. Outland, PhD
ACP policy update 2025 interview